IL165051A0 - New compounds useful for the treatment of obesity,type II diabetes and cns disorders - Google Patents

New compounds useful for the treatment of obesity,type II diabetes and cns disorders

Info

Publication number: IL165051A0
Authority: IL; Israel
Prior art keywords: obesity; diabetes; treatment; type; compounds useful
Prior art date: 2002-06-20

Application number

IL16505104A

Original Assignee

Biovitrum Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-20

Filing date

2004-11-04

Publication date

2005-12-18

2002-06-20 Priority claimed from SE0201925A external-priority patent/SE0201925D0/en

2002-07-11 Priority claimed from SE0202181A external-priority patent/SE0202181D0/en

2002-10-01 Priority claimed from SE0202908A external-priority patent/SE0202908D0/en

2003-02-10 Priority claimed from SE0300357A external-priority patent/SE0300357D0/en

2004-11-04 Application filed by Biovitrum Ab filed Critical Biovitrum Ab

2005-12-18 Publication of IL165051A0 publication Critical patent/IL165051A0/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

IL16505104A 2002-06-20 2004-11-04 New compounds useful for the treatment of obesity,type II diabetes and cns disorders IL165051A0 (en)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
SE0201925A SE0201925D0 (en)	2002-06-20	2002-06-20	New compounds
SE0202181A SE0202181D0 (en)	2002-07-11	2002-07-11	New compounds
US40612002P	2002-08-26	2002-08-26
SE0202908A SE0202908D0 (en)	2002-10-01	2002-10-01	New compounds
US43401002P	2002-12-17	2002-12-17
SE0300357A SE0300357D0 (en)	2003-02-10	2003-02-10	New compounds
US46470103P	2003-04-23	2003-04-23
PCT/SE2003/001061 WO2004000828A1 (en)	2002-06-20	2003-06-19	New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Publications (1)

Publication Number	Publication Date
IL165051A0 true IL165051A0 (en)	2005-12-18

Family

ID=30004107

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16505104A IL165051A0 (en)	2002-06-20	2004-11-04	New compounds useful for the treatment of obesity,type II diabetes and cns disorders

Country Status (13)

Country	Link
EP (1)	EP1513828A1 (en)
CN (1)	CN1662521A (en)
AU (1)	AU2003243091A1 (en)
BR (1)	BR0311952A (en)
CA (1)	CA2486989A1 (en)
EA (2)	EA011581B1 (en)
IL (1)	IL165051A0 (en)
MX (1)	MXPA04012914A (en)
NO (1)	NO20050294L (en)
NZ (3)	NZ552282A (en)
RS (1)	RS111204A (en)
SG (1)	SG156524A1 (en)
WO (1)	WO2004000828A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0308696B8 (en)	2002-03-27	2021-05-25	Axovant Sciences Gmbh	quinoline-derived compound, its preparation process, its pharmaceutical composition and its uses
SE0301446D0 (en) *	2003-05-16	2003-05-16	Astrazeneca Ab	New Compounds
TWI328009B (en)	2003-05-21	2010-08-01	Glaxo Group Ltd	Quinoline derivatives as phosphodiesterase inhibitors
BRPI0412263B1 (en)	2003-07-22	2019-10-15	Arena Pharmaceuticals, Inc.	Diaryl and aryl heteroaryl urea derivatives, use and pharmaceutical composition containing them, as well as process for preparing said composition
SE0302760D0 (en) *	2003-10-20	2003-10-20	Biovitrum Ab	New compounds
SE0303480D0 (en)	2003-12-19	2003-12-19	Biovitrum Ab	Benzofuranes
WO2005058858A1 (en) *	2003-12-19	2005-06-30	Biovitrum Ab	Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
GB0407025D0 (en) *	2004-03-29	2004-04-28	Glaxo Group Ltd	Novel compounds
AU2005244745B2 (en) *	2004-04-13	2012-05-03	Synta Pharmaceuticals Corp.	Disalt inhibitors of IL-12 production
WO2006062481A1 (en) *	2004-12-09	2006-06-15	Biovitrum Ab	New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
AR054044A1 (en) *	2005-05-23	2007-05-30	Astrazeneca Ab	CHROMAN AND TETRAHYDRONAFTALENE DERIVATIVES AS RECEPTOR MODULATORS 5 - HT6; INTERMEDIARIES IN THEIR PREPARATION; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPELO IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CNS AND OBESITY DISEASES.
US7582767B2 (en) *	2005-06-17	2009-09-01	Biovitrum Ab (Publ.)	Substituted sulphonamide compound and uses thereof
WO2007003961A2 (en) *	2005-06-30	2007-01-11	Prosidion Limited	Gpcr agonists
EP1931645B1 (en)	2005-10-07	2014-07-16	Exelixis, Inc.	N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
ATE499355T1 (en)	2005-11-03	2011-03-15	Hoffmann La Roche	ARYLSULFONYL CHROMANS AS 5-HT6 INHIBITORS
TW200736227A (en)	2005-12-23	2007-10-01	Astrazeneca Ab	New compounds III
JP2009541252A (en)	2006-06-20	2009-11-26	エフ．ホフマン−ラロシュアーゲー	Tetralin and indane derivatives and their use
CN101472883A (en)	2006-06-20	2009-07-01	弗·哈夫曼-拉罗切有限公司	Arylsulfonamidyl tetralin derivatives and uses thereof
BRPI0713742A2 (en)	2006-06-20	2013-02-13	Hoffmann La Roche	arylsulfonyl naphthalene derivatives and uses of these
TWI433839B (en)	2006-08-11	2014-04-11	Neomed Inst	Novel benzimidazole derivatives 290
WO2009074607A1 (en)	2007-12-12	2009-06-18	Glaxo Group Limited	Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en)	2008-04-02	2009-10-08	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US7888662B2 (en)	2008-06-20	2011-02-15	Varian Semiconductor Equipment Associates, Inc.	Ion source cleaning method and apparatus
US9126946B2 (en)	2008-10-28	2015-09-08	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CN103874686B (en) *	2011-05-09	2016-08-17	福马Tm有限责任公司	Piperidine derivatives and compositions for inhibiting nicotinamide phosphoribosyltransferase (NAMPT)
EP3083588B1 (en)	2013-12-20	2020-12-09	Sunshine Lake Pharma Co., Ltd.	Aromatic heterocyclic compounds and their application in pharmaceuticals
EP4119141A1 (en)	2015-06-12	2023-01-18	Axovant Sciences GmbH	Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder
EP3322415A4 (en)	2015-07-15	2019-03-13	Axovant Sciences GmbH	ARYLHERETOARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONINERGIC RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS ASSOCIATED WITH NEURODEGENERATIVE DISEASE
US20190119236A1 (en)	2016-02-23	2019-04-25	Portola Pharmaceuticals, Inc.	Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB947606A (en) *	1961-04-10	1964-01-22	Ici Ltd	N-substituted piperazines
US4808595A (en) *	1986-12-24	1989-02-28	Merck & Co., Inc.	Furopyridine sulfonamides and their opthalmological compositions
CA2158457C (en) *	1993-03-16	2001-04-17	Bertrand Leo Chenard	Naphthalene derivatives
US5597826A (en) *	1994-09-14	1997-01-28	Pfizer Inc.	Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DZ2376A1 (en) *	1996-12-19	2002-12-28	Smithkline Beecham Plc	New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.
GB9818916D0 (en) *	1998-08-28	1998-10-21	Smithkline Beecham Plc	Use
GB9904995D0 (en) *	1999-03-04	1999-04-28	Glaxo Group Ltd	Substituted aza-oxindole derivatives
GB9926302D0 (en) *	1999-11-05	2000-01-12	Smithkline Beecham Plc	Novel compounds
WO2001032660A1 (en) *	1999-11-05	2001-05-10	Nps Allelix Corp.	Compounds having 5-ht6 receptor antagonist activity
AU2001264566A1 (en) *	2000-05-05	2001-11-20	Cor Therapeutics, Inc.	Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
WO2001096336A2 (en) *	2000-06-14	2001-12-20	Warner-Lambert Company	6,5-fused bicyclic heterocycles
NZ524675A (en) *	2000-10-20	2004-09-24	Biovitrum Ab	2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl) indoles and their use in therapy
BR0209558A (en) *	2001-05-11	2004-04-20	Biovitrum Ab	New Arylsulfonamide Compounds for the Treatment of Obesity, Type II Diabetes, and Snc Disorders
YU96103A (en) *	2001-06-07	2006-08-17	F.Hoffmann-La Roche Ag.	New indole derivatives with 5-ht6 receptor affinity
US7144883B2 (en) *	2001-06-11	2006-12-05	Biovitrum Ab	Bicyclic sulfonamide compounds

2003
- 2003-06-19 SG SG200604188-3A patent/SG156524A1/en unknown
- 2003-06-19 EA EA200600975A patent/EA011581B1/en not_active IP Right Cessation
- 2003-06-19 NZ NZ552282A patent/NZ552282A/en unknown
- 2003-06-19 CA CA002486989A patent/CA2486989A1/en not_active Abandoned
- 2003-06-19 MX MXPA04012914A patent/MXPA04012914A/en not_active Application Discontinuation
- 2003-06-19 CN CN038144328A patent/CN1662521A/en active Pending
- 2003-06-19 BR BR0311952-1A patent/BR0311952A/en not_active IP Right Cessation
- 2003-06-19 NZ NZ536600A patent/NZ536600A/en unknown
- 2003-06-19 EA EA200500054A patent/EA008835B1/en not_active IP Right Cessation
- 2003-06-19 RS YU111204A patent/RS111204A/en unknown
- 2003-06-19 NZ NZ552283A patent/NZ552283A/en unknown
- 2003-06-19 AU AU2003243091A patent/AU2003243091A1/en not_active Abandoned
- 2003-06-19 WO PCT/SE2003/001061 patent/WO2004000828A1/en not_active Ceased
- 2003-06-19 EP EP03760999A patent/EP1513828A1/en not_active Ceased
2004
- 2004-11-04 IL IL16505104A patent/IL165051A0/en unknown
2005
- 2005-01-19 NO NO20050294A patent/NO20050294L/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2003243091A1 (en)	2004-01-06
EP1513828A1 (en)	2005-03-16
NO20050294L (en)	2005-02-04
SG156524A1 (en)	2009-11-26
CA2486989A1 (en)	2003-12-31
NZ552283A (en)	2008-07-31
EA008835B1 (en)	2007-08-31
RS111204A (en)	2006-12-15
EA011581B1 (en)	2009-04-28
NZ552282A (en)	2008-07-31
EA200500054A1 (en)	2005-06-30
MXPA04012914A (en)	2005-03-31
CN1662521A (en)	2005-08-31
NZ536600A (en)	2007-08-31
WO2004000828A1 (en)	2003-12-31
EA200600975A1 (en)	2006-10-27
BR0311952A (en)	2005-04-19

Publication	Publication Date	Title
IL165051A0 (en)	2005-12-18	New compounds useful for the treatment of obesity,type II diabetes and cns disorders
IL158590A0 (en)	2004-05-12	Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
PL366619A1 (en)	2005-02-07	Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
AU2003281978A1 (en)	2004-06-18	2,5-diketopiperazines for the treatment of obesity
AU2003299791A1 (en)	2004-07-22	Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
IL165257A0 (en)	2005-12-18	11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obestity anddyslipidemia
SI1474416T1 (en)	2008-02-29	Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
AU2003207717B9 (en)	2009-05-07	11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
EP1625207A4 (en)	2008-11-12	Compounds for treatment of inflammation, diabetes and related disorders
IL218909A0 (en)	2012-05-31	Treatment of diabetes
IL209842A0 (en)	2011-02-28	Compounds for the treatment of metabolic disorders
AP2005003274A0 (en)	2005-06-30	Thiazole compounds for the treatment of neurodegenerative disorders
AU2002258428A1 (en)	2002-09-12	Methods for the treatment of metabolic disorders, including obesity and diabetes
ZA200306171B (en)	2004-11-08	(Diazolo-pyridinyl)-pyrimidines for use in treatment of CNS disorders and diabetes.
AU2003279442A8 (en)	2004-04-23	2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
PL377164A1 (en)	2006-01-23	Anilinopyrazole derivatives useful for the treatment of diabetes
AU2003286728A8 (en)	2004-06-07	Compounds for the treatment of metabolic disorders
IL165242A0 (en)	2005-12-18	Treatment for diabetes
AU2003282156A8 (en)	2004-04-30	Use of prebiotics, preferably glucooligosaccharide, for the prevention of the onset of type ii diabetes
AU2002236781A1 (en)	2002-07-30	Treatment for snoring
AU2002354698A1 (en)	2003-01-21	Use of xaa-pro peptidases for the treatment of substance p-related disorders
ZA200409030B (en)	2006-02-22	New compounds useful for the treatment of obesity,type ii diabetes and CNS disorders.
AU2003239967A1 (en)	2003-12-22	Compound for the treatment of cns disorders
AU2003243214A1 (en)	2003-12-12	Salts of bis-arylsulfones for the treatment of cns disorders
ZA200308097B (en)	2004-10-18	Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes.